Jaime J Kulisevsky: Influence Statistics

Jaime J Kulisevsky

Jaime J Kulisevsky

Centro de Investigación en Red-Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain | Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant ...

Jaime J Kulisevsky: Expert Impact

Concepts for which Jaime J Kulisevsky has direct influence: Parkinson disease , Parkinsons disease , Cognitive impairment , Minor hallucinations , Essential tremor , Coppadis cohort , Mild cognitive impairment .

Jaime J Kulisevsky: KOL impact

Concepts related to the work of other authors for which for which Jaime J Kulisevsky has influence: Parkinson disease , Cognitive impairment , Deep brain stimulation , Motor symptoms , Essential tremor , Lewy bodies , Movement disorders .

KOL Resume for Jaime J Kulisevsky

Year
2022

Centro de Investigación en Red-Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain

European Huntington’s Disease Network (EHDN), Ulm, Germany

2021

Hospital de Sant Pau, 08041 Barcelona, Spain

European Huntington's DiseaseNetwork (EHDN).

2020

Universitat Autònoma de Barcelona (UAB), Spain

Hospital de la Santa Creu i Sant Pau, Barcelona

Prominent publications by Jaime J Kulisevsky

KOL-Index: 16920 . Background: Dopamine agonists have a well established role in the treatment of Parkinson’s disease. The choice of a particular dopamine agonist requires assessing the benefit-risk balance of each available medication.Objective: The present study evaluated the tolerability and safety of ropinirole against those of other dopamine agonists (bromocriptine, cabergoline, pramipexole, rotigotine, ...
Known for Dopamine Agonists | Placebo Ropinirole | Pramipexole Rotigotine | Levodopa Treatment
KOL-Index: 14025 . BACKGROUND: Dementia in Parkinson disease (PD) causes nursing home placement, caregiver distress, higher health care burden, and increased mortality. OBJECTIVE: To determine whether the microtubule-associated protein tau (MAPT) H1 haplotype and MAPT subhaplotypes play a role in the risk of PD and Parkinson disease-dementia (PDD) complex. DESIGN: Case-control genetic analysis. SETTING: ...
Known for Parkinson Disease | Mapt Haplotype | Patients Dementia | Movement Disorders
KOL-Index: 13609 . This article presents the revision process, major innovations, and clinimetric testing program for the Movement Disorder Society (MDS)-sponsored revision of the Unified Parkinson's Disease Rating Scale (UPDRS), known as the MDS-UPDRS. The UPDRS is the most widely used scale for the clinical study of Parkinson's disease (PD). The MDS previously organized a critique of the UPDRS, which cited ...
Known for Clinimetric Testing | Movement Disorder Society | Rating Scale | Unified Parkinson
KOL-Index: 12466 . BACKGROUND: Cholinergic deficits are prominent in patients who have dementia associated with Parkinson's disease. We investigated the effects of the dual cholinesterase inhibitor rivastigmine in such patients. METHODS: Patients in whom mild-to-moderate dementia developed at least 2 years after they received a clinical diagnosis of Parkinson's disease were randomly assigned to receive ...
Known for Patients Rivastigmine | Dementia Parkinsons Disease | 24 Weeks | Nausea Vomiting
KOL-Index: 12072 . BACKGROUND: Parkinson's disease (PD) is a progressive neurodegenerative disorder causing motor and non-motor symptoms that can affect independence, social adjustment and the quality of life (QoL) of both patients and caregivers. Studies designed to find diagnostic and/or progression biomarkers of PD are needed. We describe here the study protocol of COPPADIS-2015 (COhort of Patients with ...
Known for Serum Biomarkers | Parkinson Disease | Genetic Studies | Patients Caregivers
KOL-Index: 11734 . BACKGROUND/AIMS: Neurodegenerative disorders (ND) have a major impact on quality of life (QoL) and place a substantial burden on patients, their families and carers; they are the second leading cause of disability. The objective of this study was to examine QoL in persons with ND. METHODS: A battery of subjective assessments was used, including the World Health Organization Quality of Life ...
Known for Quality Life | Whoqolbref Whoqoldis | Psychometric Properties | Health Organization
KOL-Index: 11169 . Importance: Although levodopa remains the most effective oral pharmacotherapy for Parkinson disease (PD), its use is often limited by wearing off effect and dyskinesias. Management of such complications continues to be a significant challenge. Objective: To investigate the efficacy and safety of safinamide (an oral aminoamide derivative with dopaminergic and nondopaminergic actions) in ...
Known for Motor Fluctuations | Parkinson Disease | Troublesome Dyskinesia | Efficacy Safety
KOL-Index: 10833 . OBJECTIVE: To confirm that performance in verbal learning and memory test (Rey's Auditory Verbal Learning Test-RAVLT) is a helpful early neuropsychological marker of dementia of Alzheimer's type (DAT). METHODS: RAVLT was administered as part of a more extensive neuropsychological battery at baseline evaluation in 116 unselected patients referred by subjective memory complaints (SMC). ...
Known for Normal Aging | Differential Diagnosis | Verbal Learning | Mild Cognitive
KOL-Index: 10209 . We present a clinimetric assessment of the Movement Disorder Society (MDS)-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS). The MDS-UDPRS Task Force revised and expanded the UPDRS using recommendations from a published critique. The MDS-UPDRS has four parts, namely, I: Non-motor Experiences of Daily Living; II: Motor Experiences of Daily Living; III: Motor ...
Known for Movement Disorder | Disease Rating | Clinimetric Testing | Mdsupdrs Parts
KOL-Index: 10127 . Patients with dementia of Alzheimer's type (DAT) show severe impairment in recognizing famous people. The aim of the current study was to investigate if this well-known memory impairment of famous faces is already present in the preclinical phase of DAT and if the famous faces test can help to differentiate patients with mild cognitive impairment (MCI) who progress to dementia and those ...
Known for Famous People | Semantic Knowledge | Mild Cognitive Impairment | Patients Mci
KOL-Index: 10112 . Cognitive defects associated with cortical pathology may be a marker of dementia in Parkinson's disease (PD). There is a need to improve the diagnostic criteria of PD dementia (PDD) and to clarify the cognitive impairment patterns associated with PD. Current neuropsychological batteries designed for PD are focused on fronto-subcortical deficits but are not sensitive for cortical ...
Known for Cognitive Scale | Dementia Pdd | Illness Surveys | Pdcrs Items
KOL-Index: 10047 . BACKGROUND: In studies of mild cognitive impairment (MCI) in Parkinson disease (PD), patients without dementia have reported variable prevalences and profiles of MCI, likely to be due to methodologic differences between the studies. OBJECTIVE: The objective of this study was to determine frequency and the profile of MCI in a large, multicenter cohort of well-defined patients with PD using ...
Known for Parkinson Disease | Patients Mci | Mild Cognitive Impairment | Cognitive Domains
KOL-Index: 9882 . BACKGROUND: Dementia is a frequent and devastating complication in Parkinson's disease (PD). There is an intensive search for biomarkers that may predict the progression from normal cognition (PD-NC) to dementia (PDD) in PD. Mild cognitive impairment in PD (PD-MCI) seems to represent a transitional state between PD-NC and PDD. Few studies have explored the structural changes that ...
Known for Cortical Thinning | Dementia Pdd | Parkinson Disease | Pdnc Pdmci
KOL-Index: 9575 . There is controversy regarding the definition and characteristics of mild cognitive impairment in Parkinson's disease. The Movement Disorder Society commissioned a Task Force to critically evaluate the literature and determine the frequency and characteristics of Parkinson's disease-mild cognitive impairment and its association with dementia. A comprehensive PubMed literature review was ...
Known for Task Force | Cognitive Impairment | Disease Mild | Neuropsychological Tests

Key People For Parkinson Disease

Top KOLs in the world
#1
Andrew John Andrew
parkinsons disease progressive supranuclear motor fluctuations
#2
Anthony Edward Lang
parkinson disease movement disorders subthalamic nucleus
#3
Werner H Poewe
parkinson disease multiple atrophy restless legs syndrome
#4
Christopher G Goetz
parkinson disease movement disorders rating scales
#5
Charles W Olanow
parkinson disease oxidative stress motor complications
#6
Joseph J Jankovic
movement disorders parkinson disease essential tremor

Centro de Investigación en Red-Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain | Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Mas Casanovas 90, 08041, Barcelona, Spain | Movement Disorders Unit, Ne